Automate Your Wheel Strategy on KALA
With Tiblio's Option Bot, you can configure your own wheel strategy including KALA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KALA
- Rev/Share 0.039
- Book/Share -0.4922
- PB -32.5757
- Debt/Equity -3.476
- CurrentRatio 2.1018
- ROIC -1.3727
- MktCap 112582376.0
- FreeCF/Share -3.9767
- PFCF -4.3466
- PE -2.8054
- Debt/Assets 0.3091
- DivYield 0
- ROE -6.8643
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KALA | Mizuho | -- | Outperform | -- | $30 | Sept. 8, 2025 |
| Initiation | KALA | Ladenburg Thalmann | -- | Buy | -- | $12 | July 11, 2025 |
News
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Negative
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
Read More
KALA BIO Announces Chief Executive Officer Transition
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017.
Read More
About KALA BIO, Inc. (KALA)
- IPO Date 2017-07-20
- Website https://www.kalarx.com
- Industry Biotechnology
- CEO Todd Bazemore
- Employees 38